How to Get Vyvanse in Louisiana

Louisiana Allows Telehealth Prescribing for Vyvanse

Physicians, nurse practitioners, and physician assistants licensed in Louisiana can prescribe Schedule II controlled substances like Vyvanse via telehealth, provided they hold a valid Louisiana Controlled Dangerous Substance (CDS) license and a DEA registration. Louisiana updated its telehealth regulations during the COVID-19 public health emergency, and permanent rules now permit audio-video consultations for initial stimulant prescriptions.

The Ryan Haight Online Pharmacy Consumer Protection Act still applies at the federal level. Under the DEA's current telemedicine framework, a prescriber must conduct a real-time, two-way interactive video evaluation before issuing a Schedule II prescription. Phone-only visits do not qualify. Louisiana's Board of Medical Examiners reinforces this: the standard of care for a telehealth visit must match that of an in-person encounter.

Patients seeking Vyvanse through telehealth in Louisiana should confirm three things before scheduling. First, verify the provider holds a Louisiana medical license (not just a compact-state license). Second, confirm the visit will be conducted via live video. Third, ask whether the practice sends electronic prescriptions to Louisiana pharmacies, as EPCS (Electronic Prescribing for Controlled Substances) has become standard in the state.

Wait times vary. Most telehealth platforms can schedule an initial ADHD evaluation within one to two weeks. The prescription itself can be sent electronically the same day the provider writes it.

Who Can Prescribe Vyvanse in Louisiana

Any Louisiana-licensed prescriber with DEA Schedule II authority can write a Vyvanse prescription. That includes MDs, DOs, APRNs (nurse practitioners), and PAs. Louisiana grants full practice authority to APRNs who meet specific collaboration and experience requirements under the Louisiana State Board of Nursing guidelines, meaning qualified NPs can prescribe Vyvanse independently after meeting a threshold of supervised practice hours.

PAs in Louisiana prescribe under a collaborative practice agreement with a supervising physician. The supervising physician does not need to be present at the visit, but the agreement must explicitly authorize Schedule II prescribing. Patients should ask the PA's office to confirm this before booking.

Psychiatrists and psychiatric nurse practitioners are the most common prescribers for ADHD stimulants, but primary care physicians also prescribe Vyvanse frequently. A 2019 analysis of prescribing data found that roughly 50% of stimulant prescriptions in the United States originated from primary care settings, not specialty psychiatry. In rural Louisiana parishes where psychiatric access is limited, primary care and telehealth fill a significant gap.

Pediatricians can prescribe Vyvanse for children aged 6 and older. The FDA-approved labeling supports lisdexamfetamine for pediatric ADHD at doses of 30 mg to 70 mg daily, titrated based on tolerability and clinical response.

What Labs and Evaluations Are Needed Before Starting

Vyvanse does not require routine laboratory testing before initiation. No blood draw is mandatory. The essential components of a pre-prescribing evaluation are clinical, not biochemical.

A structured ADHD diagnostic assessment is the baseline requirement. The American Academy of Pediatrics recommends using validated rating scales such as the Vanderbilt Assessment or the Adult ADHD Self-Report Scale (ASRS) as part of the diagnostic workup. The prescriber should document symptom history, functional impairment in at least two settings, and the exclusion of conditions that mimic ADHD (anxiety disorders, sleep disorders, thyroid dysfunction).

Cardiovascular screening is standard practice. The American Heart Association recommends a focused cardiac history and blood pressure measurement before prescribing any stimulant. If a patient reports a family history of sudden cardiac death, structural heart disease, or arrhythmia, the prescriber may order an electrocardiogram before starting therapy. Routine EKGs are not universally required for all patients starting stimulants.

Vital signs at baseline should include resting heart rate and blood pressure. Lisdexamfetamine can increase both. A meta-analysis of stimulant trials showed mean systolic blood pressure increases of 2 to 4 mmHg and heart rate increases of 3 to 6 bpm with therapeutic doses.

For binge eating disorder, the prescriber should document a DSM-5 diagnosis with binge frequency and duration. Wigal et al. (2017) reported that lisdexamfetamine reduced binge eating days per week from a mean of 4.5 to 1.1 in a 12-week, forced-dose titration study, supporting its use in this population.

Weight and BMI measurements at baseline are strongly recommended, as stimulants can suppress appetite and reduce body weight. Follow-up monitoring every one to three months during dose titration is considered best practice.

Louisiana Medicaid Does Not Cover Vyvanse

Louisiana Medicaid does not include Vyvanse on its preferred drug list for ADHD or binge eating disorder. Patients covered by Louisiana Medicaid who need a stimulant are typically directed toward generic alternatives like mixed amphetamine salts (generic Adderall) or methylphenidate, both of which are covered.

A prescriber can submit a prior authorization request to Louisiana Medicaid arguing medical necessity for brand Vyvanse. Approval rates are low. The most common accepted justification is documented therapeutic failure or intolerance to at least two preferred stimulant agents. "Therapeutic failure" means the patient tried the drug at adequate doses for adequate duration and did not achieve acceptable symptom control, or experienced intolerable adverse effects.

For patients with commercial insurance, Vyvanse coverage is more common but still usually requires prior authorization. Documentation requirements typically include the ADHD diagnosis with supporting symptom scales, prior medication trials, and the prescriber's clinical rationale for lisdexamfetamine specifically.

The cash price for brand-name Vyvanse 30-day supply ranges from approximately $350 to $430 at major chain pharmacies in Louisiana. Takeda offers a manufacturer savings program that can reduce the cost to as low as $30 per month for commercially insured patients. This coupon does not apply to government insurance programs (Medicaid, Medicare, Tricare). Generic lisdexamfetamine became available in August 2023 after Takeda's patent settlement with generic manufacturers; generic pricing typically falls between $50 and $150 for a 30-day supply depending on pharmacy and dose.

503A Compounding Pharmacies in Louisiana

Louisiana licenses 503A compounding pharmacies under the Louisiana Board of Pharmacy. These pharmacies can compound patient-specific prescriptions for lisdexamfetamine when a licensed prescriber writes an individual order. They cannot produce batch quantities for general distribution without a patient-specific prescription.

A common reason patients seek compounded lisdexamfetamine is dose customization. The commercially available capsules come in fixed strengths (10, 20, 30, 40, 50, 60, and 70 mg). Some patients, particularly children or those who are sensitive to dose changes, may need an intermediate dose that falls between these increments. A 503A pharmacy can prepare a capsule at a non-standard dose.

Another reason is formulation flexibility. Some patients cannot swallow capsules and prefer a liquid suspension. While the brand capsule can be opened and dissolved in water per the FDA prescribing information, a compounding pharmacy can prepare a stable flavored suspension with a defined beyond-use date.

503A pharmacies in Louisiana can ship compounded prescriptions within the state. Interstate shipping of compounded Schedule II substances is subject to both DEA regulations and the receiving state's pharmacy laws. Patients relocating from another state should confirm that their new Louisiana pharmacy can receive the transferred prescription electronically, as Louisiana requires EPCS for all Schedule II prescriptions.

How to Transfer a Vyvanse Prescription to Louisiana

Federal law prohibits the transfer of Schedule II prescriptions between pharmacies. This is a hard rule. If a patient moves from Texas to Louisiana, their existing Vyvanse prescription at a Texas pharmacy cannot be called in, faxed, or electronically transferred to a Louisiana pharmacy.

The patient needs a new prescription from a Louisiana-licensed prescriber or from a prescriber licensed in their former state who also holds Louisiana prescribing authority. In practice, this means scheduling a visit (in-person or telehealth) with a Louisiana provider who can issue a new electronic prescription to a Louisiana pharmacy.

Patients can request their medical records, including ADHD evaluations, prior medication history, and rating scales, from their previous provider. Sharing these records with the new Louisiana prescriber speeds up the evaluation. Most providers will not require a full re-evaluation if recent documentation is thorough.

Timing matters. Patients should start the process at least two to three weeks before their current supply runs out. Schedule II prescriptions cannot be refilled, so a gap in coverage means a gap in medication. The prescriber writes a new prescription each month.

Prior Authorization Requirements in Louisiana

Prior authorization for Vyvanse in Louisiana depends on the patient's insurance plan. Louisiana Medicaid, as noted, does not cover Vyvanse on its preferred drug list and requires extensive justification. Commercial insurers each have their own prior authorization criteria, but common requirements overlap.

Most plans require documentation of at least one of the following: a confirmed ADHD diagnosis using DSM-5 criteria, failure or intolerance of a preferred formulary stimulant (often generic mixed amphetamine salts or methylphenidate), and the prescriber's rationale for choosing lisdexamfetamine. For binge eating disorder, insurers may require documentation that the patient meets DSM-5 criteria for moderate-to-severe BED, with binge episodes occurring at least once per week for three months.

The AACE/ACE guidelines recommend that clinicians document baseline weight, BMI, and binge frequency at the start of treatment and at each follow-up. This documentation strengthens prior authorization requests by showing objective treatment targets.

Prior authorization turnaround times in Louisiana range from 24 to 72 hours for standard requests. Urgent requests, filed when the patient has no medication supply, can be processed in under 24 hours. If the prior authorization is denied, the prescriber can file a peer-to-peer appeal. According to the American Academy of Family Physicians, peer-to-peer reviews overturn approximately 40% to 60% of initial stimulant prior authorization denials when the prescriber provides adequate documentation of treatment history.

Monitoring and Follow-Up After Starting Vyvanse

After the initial prescription, follow-up visits should occur every 30 days during dose titration. Louisiana prescribers must issue a new prescription each month for Schedule II medications. No refills are permitted under federal law.

The Wigal et al. study established that lisdexamfetamine produces significant ADHD symptom reduction within the first week of treatment, with continued improvement through week four of dose optimization. Clinicians typically titrate from 30 mg upward in 10 mg or 20 mg increments at weekly intervals, stopping when symptoms are adequately controlled or side effects emerge.

Monitoring parameters include blood pressure, heart rate, weight, appetite, sleep quality, and mood. The FDA label for lisdexamfetamine carries warnings for cardiovascular events, psychiatric adverse effects (new or worsening psychosis, mania), and growth suppression in pediatric patients. Height and weight should be tracked on a growth chart for children and adolescents at every visit.

"Patients on long-term stimulant therapy should have periodic reassessment of the need for continued treatment," per the American Academy of Pediatrics Clinical Practice Guideline for ADHD. This means at least one formal reassessment per year, including updated symptom rating scales and a review of functional outcomes.

Once stable, many patients transition to visits every three to six months, though the prescription itself must still be issued monthly. Louisiana prescribers can write up to 90-day supplies of Schedule II stimulants using sequential prescriptions (three 30-day prescriptions dated to be filled sequentially), reducing the frequency of required office visits while complying with DEA rules.

The maximum recommended dose for ADHD is 70 mg daily in both adults and children aged 6 and older. For binge eating disorder in adults, the therapeutic dose range is 50 mg to 70 mg daily, initiated at 30 mg and titrated over four weeks.